首页> 外国专利> Methods for modulating the aggregation of amyloids in an individual, for the treatment of a disease condition associated with amyloidosis, composition for modulating amyloidosis, and, methods for inhibiting the amyloid deposits associated with iapp in an individual, to inhibit iapp fibrillogenesis in an individual , to reduce aggregates of amyloids associated with iapp in an individual, to modulate damage associated with amyloids in cells, and to modulate amyloidosis in vivo or ex vivo

Methods for modulating the aggregation of amyloids in an individual, for the treatment of a disease condition associated with amyloidosis, composition for modulating amyloidosis, and, methods for inhibiting the amyloid deposits associated with iapp in an individual, to inhibit iapp fibrillogenesis in an individual , to reduce aggregates of amyloids associated with iapp in an individual, to modulate damage associated with amyloids in cells, and to modulate amyloidosis in vivo or ex vivo

机译:调节个体中淀粉样蛋白聚集,治疗与淀粉样变性病相关的疾病的方法,调节淀粉样变性病的组合物,以及抑制个体中与iapp相关的淀粉样蛋白沉积物的方法,以抑制个体中iapp的原纤维形成,减少个体中与iapp相关的淀粉样蛋白的聚集体,调节与细胞中淀粉样蛋白相关的损伤,并调节体内或离体的淀粉样变性

摘要

"METHODS FOR MODULATING THE AGGREGATION OF AMYLOIDES IN AN INDIVIDUAL, FOR THE TREATMENT OF A SICK STATE ASSOCIATED WITH AMYLOIDOSIS, COMPOSITION FOR MODULAR AMYLOIDOSIS, AND, METHODS FOR INHIBITING EMITORIOUS EMYZOID EMYPOCOPPED EMYPHOPID EMYPOP EMITTED EMYPOP EMITTED EMAPPIRATED EMIPAPE INDIVIDUAL, TO REDUCE IAPP-ASSOCIATED AMYLOID AGGREGATES IN ONE INDIVIDUAL, TO MODULAR DAMAGE ASSOCIATED WITH AMYLOIDS IN CELLS, AND TO MODULAR AMYLOIDOSIS IN VIVO OU.EX LIVE ". Therapeutic compounds and methods for modulating amyloid aggregation in an individual, whatever their clinical status, are described. The aggregation of amyloids is modulated by administering to an individual an effective amount of a therapeutic compound of formula (1): or a pharmaceutically acceptable salt or ester, so that modulation of the aggregation of amyloids occurs. R ^ 1 ^ and R ^ 2 ^ are each independently a hydrogen atom or a substituted or unsubstituted aryl or aliphatic group. Z and Q are each independently a carbonyl (C = O), thiocarbonyl (C = S), sulfonyl (SO ~ 2 ~), or sulfoxide (S = O) group. "k" and "m" are 0 or 1, since when k is 1, R ^ 1 ^ is not a hydrogen atom, and when m is 1, R ^ 2 ^ is not a hydrogen atom. In one embodiment, at least one of k or m must equal 1. "p" and "s" are each independently selected positive integers so that the biodistribution of the therapeutic compound to a desired targeting site is not prevented while maintaining activity of the therapeutic compound. T is a linking group and Y is a group of formula: -AX, where A is an anionic group at physiological pH, and X is a cationic group.
机译:“用于调节个体中淀粉样蛋白的聚集,用于治疗与淀粉样变性相关的病态,模块化淀粉样变性的组成的方法,以及用于抑制致病性淀粉样的二肽,经酶联的,二肽的,经酶联的,二肽的,经酶联的,经酶联的,二肽的,经酶联处理的,经酶联处理的方法淀粉样蛋白在一个个体中聚集,与细胞中的淀粉样蛋白相关的模块损伤,以及活体OU.EX LIVE中的模块化淀粉样变性。描述了调节个体中淀粉样蛋白聚集的治疗性化合物和方法,无论其临床状态如何。通过向个体施用有效量的式(1)的治疗化合物:或药学上可接受的盐或酯来调节淀粉状蛋白的聚集,从而发生淀粉状蛋白聚集的调节。 R ^ 1 ^和R ^ 2 ^各自独立地为氢原子或取代或未取代的芳基或脂族基团。 Z和Q各自独立地为羰基(C = O),硫代羰基(C = S),磺酰基(SO〜2〜)或亚砜(S = O)。 “ k”和“ m”为0或1,因为当k为1时,R ^ 1 ^不是氢原子,而当m为1时,R ^ 2 ^不是氢原子。在一个实施方案中,k或m中的至少一个必须等​​于1。“ p”和“ s”各自独立地选择为正整数,从而在保持治疗剂活性的同时,不阻止治疗剂化合物向所需靶位的生物分布。复合。 T是连接基团,Y是下式的基团:-AX,其中A是在生理pH下的阴离子基团,而X是阳离子基团。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号